Claritev Corp

CTEV

Market cap $516M

Claritev Corporation (CTEV) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. Management will be presenting on Thursday, January 15, 2026 at 7:30 a.m. PT. A live webcast and audio archive of the presentation will be available through the investor relations section of Claritev's.

Claritev Corporation (CTEV) Presents at Bank of America Leveraged Finance Conference Transcript

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation Announces Participation at Upcoming Conferences.

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the pricing of an underwritten public offering (the “Offering”) of 1,500,000 shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), by certain affiliates of Hellman & Friedman (collectively, the “Selling Stockholders”) at a price.

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, today announced the commencement of an underwritten public offering (the “Offering”) of 1,500,000 shares of its Class A common stock, par value $0.0001 per share (the “Class A common stock”), by certain affiliates of Hellman & Friedman (collectively, the “Selling Stockholders”). The.

Claritev Corporation ( CTEV ) Q3 2025 Earnings Call November 7, 2025 8:00 AM EST Company Participants Todd Friedman - Vice President of Investor Relations Travis Dalton - CEO, President & Chairman Doug Garis - Executive VP & CFO Conference Call Participants Joshua Raskin - Nephron Research LLC Daniel Grosslight - Citigroup Inc. Exchange Research Jessica Tassan - Piper Sandler & Co., Research Division Presentation Operator Hello, everyone, and thank you for joining us today for the Claritev Corporation Third Quarter Earnings Call. My name is Sami, and I'll be coordinating your call today.

Claritev Corporation (CTEV) came out with a quarterly loss of $4.07 per share versus the Zacks Consensus Estimate of a loss of $3.12. This compares to a loss of $1.85 per share a year ago.

MCLEAN, Va.--(BUSINESS WIRE)--Claritev Corporation Reports Third Quarter 2025 Results.

MCCLEAN, Va. & RIYADH, Saudi Arabia--(BUSINESS WIRE)--Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a global leader in healthcare analytics and claims analysis, today announced a strategic investment in Klaim, Inc., an AI-driven healthcare payment-acceleration solutions provider. The investment will help fund the launch of a co-branded Payment Acceleration Service integrated within Claritev's extensive provider network, helping healthcare organizations gain faster and more pr.